Review Article
Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension
Table 1
Serial functional, hemodynamic, and laboratory parameters before and after the tocilizumab treatment.
| | Pretreatment | 3 months | 6 months | 9 months | 12 months |
| | NYHA functional class | III | II | I | I | I | | 6MWD (m) | 310 | 434 | ND | ND | 663 | | Mean PAP (mmHg) | 43 | 31 | ND | ND | 27 | | PCWP (mmHg) | 11 | 4 | ND | ND | 4 | | RAP (mmHg) | 12 | 2 | ND | ND | 3 | | Systemic venous oxygen saturation (%) | 52.1 | 69.4 | ND | ND | 75.3 | | Cardiac output (L/min) | 5.5 | 4.5 | ND | ND | 4.4 | | PVR (wood unit) | 5.8 | 5.6 | ND | ND | 5.3 | | Doppler systolic PAP (mmHg) | 100 | 90 | 72 | 51 | 54 | | BNP (pg/mL) | 181 | 48 | 44 | 46 | 37 | | CRP (mg/dL) | 9.01 | 0.54 | 0.25 | 0.12 | 0.04 | | IgG (mg/dL) | 6,451 | 3,266 | 2,679 | 2,433 | 2,238 | | Hemoglobin (g/dL) | 8.0 | 12.9 | 13.9 | 13.0 | 12.8 | | IL-6 (pg/mL) | 41.8 | 1,100 | 801 | 806 | 756 |
|
|
ND, 6MWD and hemodynamic assessment by right heart catheterization were not done at 6 and 9 months.
|
